Wells Fargo & Company Vallon Pharmaceuticals, Inc. Transaction History

Wells Fargo & Company

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	BUY	$0.27 - $0.88 $0 - $0	1 Added 1.75%	58 $0
Q4 2022 Feb 13, 2023	BUY	$0.22 - $0.52 $3 - $8	16 Added 39.02%	57 $0
Q3 2022 Nov 14, 2022	BUY	$0.3 - $0.68 $7 - $17	26 Added 173.33%	41 $0
Q2 2022 Aug 12, 2022	BUY	$0.42 - $2.27 $0 - $2	1 Added 7.14%	15 $0
Q1 2021 May 13, 2021	BUY	$4.32 - $7.83 $60 - $109	14 New	14 $0

Ticker VLON
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 10,512,800
Description
Vallon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medications for central nervous system disorders with a focus on abuse-deterrent medications. Its lead investigational product candidate is ADAIR, an abuse-deterrent oral formulation of immediate-release dextroamphetamine for the ...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.